Show simple item record

dc.contributor.authorBierlaire, Damien
dc.contributor.authorMauguin, Sylvie
dc.contributor.authorBroult, Julien
dc.contributor.authorMusso, Didier
dc.date.accessioned2021-07-23T02:32:42Z
dc.date.available2021-07-23T02:32:42Z
dc.date.issued2017
dc.identifier.urihttps://pubmed.ncbi.nlm.nih.gov/28185278/en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12663/2636
dc.description.abstractBackground: Between October 2013 and March 2014, French Polynesia experienced the largest Zika virus (ZIKV) outbreak ever described before the emergence of ZIKV in the Americas in 2015. As arbovirus transfusion-transmitted (TT) infections have been previously reported, we hypothesized that transfusion of blood products could also transmit ZIKV. Study design and methods: Mitigation strategies to prevent ZIKV-TT infections included nonspecific measures and the implementation of a laboratory developed ZIKV-specific nucleic acid testing (NAT) assay. Donor sera were tested in pools of 3 and constitutive sera of ZIKV-reactive pools were tested individually. Donor sera were tested prospectively and retrospectively. A posttransfusion follow-up of a patient transfused with ZIKV RNA-reactive blood products was implemented. Results: NAT detected 42 blood donor sera as ZIKV RNA reactive of 1505 tested (2.8%). Thirty ZIKV RNA-reactive blood products collected before the implementation of NAT were transfused to 26 recipients. Posttransfusion investigations were conducted by the hemovigilance unit and data were available for 12 recipients. Symptomatic ZIKV-TT infections were not reported. Conclusion: Predonation screening of blood donors, postdonation information, products discard, and quarantine of blood products were not effective enough to prevent transfusion of ZIKV RNA-reactive blood products. ZIKV NAT was an effective measure once implemented to prevent transfusion of ZIKV RNA-reactive blood products but it is difficult to evaluate the effectiveness of this measure to prevent ZIKV-TT infection, which is a rare event.en_US
dc.languageEnglishen_US
dc.subjectZika Research Projecten_US
dc.subjectZika virusen_US
dc.subjectBlood Component Transfusionen_US
dc.subjectBlood Donorsen_US
dc.subjectScreeningen_US
dc.subjectFrench Polynesiaen_US
dc.titleZika virus and blood transfusion: the experience of French Polynesiaen_US
eihealth.countryOthersen_US
eihealth.categoryEpidemiology and epidemiological studiesen_US
eihealth.typePublished Articleen_US
eihealth.maincategoryProtect Health Care Workers / Proteger la Salud de los Trabajadoresen_US
dc.relation.ispartofjournalTransfusionen_US
dc.contributor.corporatenameHemovigilance Unit, Tahiti, French Polynesiaen_US
dc.contributor.corporatenameFrench Polynesian Blood Bank, Hôpital du Taaone, Tahiti, French Polynesiaen_US
dc.contributor.corporatenameUnit of Emerging Infectious Diseases, Institut Louis Malardé, Tahiti, French Polynesiaen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record